Evidence map›Paper›PMID 37179294›Full record

ArticleAIDS research and therapy2023

Dual trajectories of antiretroviral therapy adherence and polypharmacy in women with HIV in the United States.

Abubaker Ibrahim Elbur, Musie Ghebremichael, Deborah Konkle-Parker, Deborah L Jones, Shelby Collins, Adaora A Adimora, Michael F Schneider, Mardge H Cohen, Bani Tamraz, Michael Plankey and 4 more

Open access · goldAbstract read
In one paragraph

Article in AIDS research and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 14 institutions in 2 countries.

Abubaker Ibrahim ElburCenter for Global Health, Massachusetts General Hospital, Boston, MA, USA. bakarelbu@yahoo.co.uk.
Musie GhebremichaelThe Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Deborah Konkle-ParkerSchools of Nursing, Medicine and Population Health, University of Mississippi Medical Center, Jackson, MS, USA.
Deborah L JonesDepartment of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Shelby CollinsDivision of Infectious Disease, Emory University School of Medicine, Atlanta, GA, USA.
Adaora A AdimoraDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Michael F SchneiderDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Mardge H CohenDepartment of Medicine, Stroger Hospital of Cook County, Chicago, IL, USA.
Bani TamrazSchool of Pharmacy, University of California, San Francisco, San Francisco, CA, USA.
Michael PlankeyDepartment of Medicine, Division of General Internal Medicine, Georgetown University Medical Center, Washington, DC, USA.
Tracey WilsonSchool of Public Health, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Adebola AdedimejiDept of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Jessica E HabererCenter for Global Health, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Denise L JacobsonCenter for Biostatistics in AIDS Research, Department of Biostatistics , Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Albert Einstein College of Medicine · USCancer Research And Biostatistics · USCenter for Global Health · USEmory University · USGeorgetown University · USHarvard University · USJohn H. Stroger, Jr. Hospital of Cook County · USJohns Hopkins University · USRagon Institute of MGH, MIT and Harvard · USSUNY Downstate Health Sciences University · USUniversity of California, San Francisco · USUniversity of Miami · USUniversity of Mississippi Medical Center · USUniversity of North Carolina at Chapel Hill · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Sex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
Sex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2M
MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146241 · NHLBI · EMORY UNIVERSITY · PI Cecile Delille Lahiri, Anandi Nayan Sheth · 2019 to 2026
$24.2M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI073961NIAID NIH HHS T32 AI007433NIMH NIH HHS K24 MH114732NIMH NIH HHS P30 MH116867NIMH NIH HHS R25 MH119857
6 · The paper itself

Abstract

backgroundPolypharmacy, using five or more medications, may increase the risk of nonadherence to prescribed treatment. We aimed to identify the interrelationship between trajectories of adherence to antiretroviral therapy (ART) and polypharmacy.

methodsWe included women with HIV (aged ≥ 18) enrolled in the Women's Interagency HIV Study in the United States from 2014 to 2019. We used group-based trajectory modeling (GBTM) to identify trajectories of adherence to ART and polypharmacy and the dual GBTM to identify the interrelationship between adherence and polypharmacy.

resultsOverall, 1,538 were eligible (median age of 49 years). GBTM analysis revealed five latent trajectories of adherence with 42% of women grouped in the consistently moderate trajectory. GBTM identified four polypharmacy trajectories with 45% categorized in the consistently low group.

conclusionsThe joint model did not reveal any interrelationship between ART adherence and polypharmacy trajectories. Future research should consider examining the interrelationship between both variables using objective measures of adherence.

Indexed as

HIV InfectionsAnti-Retroviral AgentsFemaleHumansMedication AdherenceMiddle AgedPolypharmacyUnited StatesAnti-Retroviral Agents

Identifiers

PMID37179294
PMCPMC10182649
OpenAlexW4376288626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.